Top Markets
Coin of the day
Moleculin Biotech, Inc. Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX
Hisse Senetlerindeki Sıralama #35911
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to... Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Hisse Fiyatı
$0.6155
Son senkronizasyon: 2026-08-14
Piyasa Değeri
$3.28M
Değişim (1 gün)
7.74%
Değişim (1 yıl)
-96.39%
Ülke
US
Ticaret Moleculin Biotech, Inc. (MBRX)

Kategori

Moleculin Biotech, Inc. (MBRX) için temettü verimi geçmişi
Moleculin Biotech, Inc. (hisse sembolü: MBRX) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Moleculin Biotech, Inc. (MBRX) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)